
Sign up to save your podcasts
Or


In this interview, Jeroen Bax, PhD, MD, FACC; Stefan Anker, MD, PhD; and Sherry-Ann Brown, MD, PhD, FACC, discuss the ESC Congress 2021 late breaker EMPEROR-Preserved, which evaluates the effect of empagliflozin for risk of cardiovascular death and hospitalisation for patients with heart failure and a preserved fraction with and without diabetes. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
By American College of Cardiology3.8
5454 ratings
In this interview, Jeroen Bax, PhD, MD, FACC; Stefan Anker, MD, PhD; and Sherry-Ann Brown, MD, PhD, FACC, discuss the ESC Congress 2021 late breaker EMPEROR-Preserved, which evaluates the effect of empagliflozin for risk of cardiovascular death and hospitalisation for patients with heart failure and a preserved fraction with and without diabetes. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

137 Listeners

320 Listeners

498 Listeners

169 Listeners

885 Listeners

289 Listeners

140 Listeners

1,156 Listeners

41 Listeners

195 Listeners

90 Listeners

364 Listeners

431 Listeners

371 Listeners

32 Listeners